hero section gradient
15 handpicked stocks

U.S. Exporters Target Indonesian Growth

The United States and Indonesia have announced a landmark trade agreement, eliminating tariffs on over 99% of U.S. exports. This deal creates a significant opportunity for American companies in the industrial, food, and technology sectors to expand into a large and growing market.

Author avatar

Han Tan | Market Analyst

Published on July 23

Your Basket's Financial Footprint

Market capitalisation breakdown for the basket 'U.S. Exporters Target Indonesian Growth'.

Key Takeaways for Investors:
  • Large-cap dominance suggests lower volatility and closer alignment with broad market performance, likely reducing idiosyncratic risk.
  • Suitable as a core, long-term portfolio holding rather than a speculative, concentrated growth position.
  • Expect steady, incremental value over time; avoid expecting explosive short-term gains.
Total Market Cap
  • ITW: $74.96B

  • GFS: $19.73B

  • HON: $132.74B

  • Other

About This Group of Stocks

1

Our Expert Thinking

The landmark U.S.-Indonesia trade agreement eliminates tariffs on over 99% of American exports, creating a massive opportunity for established U.S. companies. This deal opens access to one of the world's largest and fastest-growing consumer markets, particularly benefiting industrial, food, and technology sectors with the infrastructure to scale quickly.

2

What You Need to Know

These are established American companies with extensive global supply chains and proven ability to expand into new markets. The removal of trade barriers means these firms can now compete more effectively in Indonesia's growing economy, potentially leading to increased sales volumes and revenue growth from reduced export costs.

3

Why These Stocks

Each company was handpicked by professional analysts based on their direct exposure to Indonesian market opportunities. These firms operate in sectors specifically mentioned in the trade agreement and have the operational capacity to capitalize on zero tariffs and simplified regulatory standards that the deal provides.

Why You'll Want to Watch These Stocks

🚀

First-Mover Advantage

These companies are positioned to be among the first to capitalize on Indonesia's newly opened market. With tariffs eliminated, they can move quickly while competitors are still figuring out their strategy.

🌏

Massive Market Unlock

Indonesia is the world's fourth most populous country with a rapidly growing middle class. This trade deal just opened the door to 270 million potential new customers for American businesses.

💰

Instant Cost Savings

Zero tariffs mean these companies can immediately reduce their export costs and improve profit margins. That's money that goes straight to the bottom line and potentially to shareholders.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions